JP2019529481A5 - - Google Patents

Download PDF

Info

Publication number
JP2019529481A5
JP2019529481A5 JP2019516972A JP2019516972A JP2019529481A5 JP 2019529481 A5 JP2019529481 A5 JP 2019529481A5 JP 2019516972 A JP2019516972 A JP 2019516972A JP 2019516972 A JP2019516972 A JP 2019516972A JP 2019529481 A5 JP2019529481 A5 JP 2019529481A5
Authority
JP
Japan
Prior art keywords
theta
crystalline form
compound
crystal
starting temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019516972A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019529481A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/054227 external-priority patent/WO2018064441A1/en
Publication of JP2019529481A publication Critical patent/JP2019529481A/ja
Publication of JP2019529481A5 publication Critical patent/JP2019529481A5/ja
Withdrawn legal-status Critical Current

Links

JP2019516972A 2016-09-30 2017-09-29 胆汁酸誘導体の結晶形態 Withdrawn JP2019529481A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662402813P 2016-09-30 2016-09-30
US62/402,813 2016-09-30
PCT/US2017/054227 WO2018064441A1 (en) 2016-09-30 2017-09-29 Crystalline forms of a bile acid derivative

Publications (2)

Publication Number Publication Date
JP2019529481A JP2019529481A (ja) 2019-10-17
JP2019529481A5 true JP2019529481A5 (enExample) 2020-09-17

Family

ID=61760943

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019516972A Withdrawn JP2019529481A (ja) 2016-09-30 2017-09-29 胆汁酸誘導体の結晶形態

Country Status (11)

Country Link
US (1) US20200024299A1 (enExample)
EP (1) EP3518937A4 (enExample)
JP (1) JP2019529481A (enExample)
KR (1) KR20190057108A (enExample)
CN (1) CN109963567A (enExample)
AU (1) AU2017336803A1 (enExample)
BR (1) BR112019006242A2 (enExample)
CA (1) CA3038534A1 (enExample)
IL (1) IL265621A (enExample)
MX (1) MX2019003684A (enExample)
WO (1) WO2018064441A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ,インク. Gpr119アゴニスト
MX2022010548A (es) 2020-02-28 2022-09-23 Kallyope Inc Agonistas de gpr40.
MX2022014505A (es) 2020-05-19 2022-12-13 Kallyope Inc Activadores de la ampk.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2040713T3 (da) * 2006-06-27 2014-09-29 Intercept Pharmaceuticals Inc Galdesyrederivater som fxr-ligander til forebyggelsen eller behandlingen af fxr-medierede sygdomme eller tilstande
EP2527345B1 (en) * 2006-10-16 2015-12-16 Thesan Pharmaceuticals, Inc. Therapeutic pyrazolyl thienopyridines
EP2202228B1 (en) * 2007-10-15 2014-12-10 Takeda Pharmaceutical Company Limited Amide compounds and use of the same
EP2468762A1 (en) * 2010-11-30 2012-06-27 Dr. Falk Pharma Gmbh Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size
ES2822375T3 (es) * 2012-06-19 2021-04-30 Intercept Pharmaceuticals Inc Preparación de la forma no cristalina del ácido obeticólico
NZ707389A (en) * 2012-10-26 2018-08-31 Intercept Pharmaceuticals Inc Process for preparing bile acid derivatives
WO2014085474A1 (en) * 2012-11-28 2014-06-05 Intercept Pharmaceuticals, Inc. Treatment of pulmonary disease
HUP1300504A2 (en) * 2013-08-27 2015-03-30 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Sorafenib salts
EP3331896A4 (en) * 2015-08-07 2019-08-14 Intercept Pharmaceuticals, Inc. PROCESS FOR THE PRODUCTION OF GALLENIC ACID AND DERIVATIVES THEREOF
KR20180052756A (ko) * 2015-09-24 2018-05-18 인터셉트 파마슈티컬즈, 인크. 담즙산 유도체 제조를 위한 방법 및 중간체

Similar Documents

Publication Publication Date Title
AU730776B2 (en) Novel modifications of 2-amino-4-(4-flourobenzylamino)-1- ethoxycarbonylaminobenzene, and processes for their preparation
JP2020511461A5 (enExample)
EP2785701B1 (en) Crystalline form of carbazitaxel and process for preparation thereof
JP2014501282A5 (enExample)
JP2014521726A5 (enExample)
JP7473486B2 (ja) Rad1901-2hclの多形形態
JP2015010091A5 (enExample)
JP2019505532A5 (enExample)
JP2010514725A5 (enExample)
RU2017142958A (ru) Кристаллы азабициклического соединения
JP2015516425A5 (enExample)
JP2013520488A5 (enExample)
JP2009534373A5 (enExample)
AU2014259029A1 (en) Polymorphic forms of nilotinib hydrochloride
JP2020502224A5 (enExample)
JP2013505234A (ja) 3−(4−アミノ−1−オキソ−1,3−ジヒドロ−イソインドール−2−イル)−ピペリジン−2,6−ジオンの固形体およびその製造方法
JP2012509281A5 (enExample)
JP2016510767A5 (enExample)
CN112469717B (zh) 用于纯化艾沙康唑鎓硫酸盐的方法
JP2005529084A5 (enExample)
JP2016172741A5 (enExample)
WO2015011659A1 (en) Crystalline polymorphic forms of regorafenib and processes for the preparation of polymorph i of regorafenib
CN106604916A (zh) 钾离子竞争性酸阻滞剂的晶型及其制备方法
JP2019512542A5 (enExample)
JP2025510826A5 (enExample)